Epitalon Biohacker and Longevity Stack Protocol: Doses, Cycles, and Evidence

What Is Epitalon and Why Do Biohackers Use It?

Epitalon is a four-amino-acid peptide (Ala-Glu-Asp-Gly) first isolated and synthesized by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. Khavinson's group identified it as the active fragment of epithalamin, a polypeptide complex extracted from bovine pineal glands. The pineal gland regulates circadian rhythm and melatonin secretion, and both decline measurably with age. Biohackers who follow the work of longevity-focused clinicians (Attia, Huberman, Brecka and others in that tier) use Epitalon primarily because of its proposed ability to activate telomerase, the enzyme that extends telomeric DNA repeats.

Telomere attrition is one of the nine hallmarks of aging described by López-Otín et al. In their foundational 2013 Cell paper [1]. Short telomeres correlate with higher all-cause mortality in large epidemiological cohorts [2]. The logic of the Epitalon stack is straightforward: if a peptide can slow or partially reverse telomere shortening, it may slow one measurable axis of biological aging.

The Khavinson Research Background

Khavinson's team published extensively in Russian and international journals across four decades. A 2003 Bulletin of Experimental Biology and Medicine paper reported that Epitalon increased telomerase activity in human fetal fibroblasts and somatic cells in vitro, and elongated telomeres by approximately 33% in treated cell lines compared with controls [3]. The same group showed Epitalon reduced chromosomal aberrations in aging human diploid cells by roughly 2.4-fold relative to untreated cultures [3].

Pineal and Melatonin Effects

A second line of Khavinson's work demonstrated that epithalamin (the parent complex) restored melatonin amplitude in aging rats and in a small cohort of elderly women [4]. Because Epitalon is the synthetic analog, the community extrapolates this effect. Melatonin itself has antioxidant properties documented in peer-reviewed literature, and age-related decline in nocturnal melatonin is well established [4].

Evidence Quality: Grading What We Actually Know

The evidence base for Epitalon is real but narrow. Grading it honestly matters before any protocol discussion.

Telomerase and Telomere Data (In Vitro and Animal)

The strongest mechanistic evidence is in vitro. The 2003 Anisimov and Khavinson study in human fibroblasts showed statistically significant telomerase induction and telomere elongation [3]. Animal lifespan data are more striking: Anisimov's group published a 2006 Gerontology paper reporting that epithalamin treatment in female SHR rats extended mean lifespan by 26% and maximum lifespan by 13% versus saline controls, with associated reductions in tumor incidence [5]. Epitalon showed comparable results in later mouse experiments by the same institute.

Evidence grade: Level 3 (animal and in vitro). No peer-reviewed randomized controlled trial in humans has been published as of the 2025 review date.

Human Observational Data

Khavinson's 1997 report in the journal Gerontology described a 15-year follow-up of elderly patients in St. Petersburg residential homes who received epithalamin (not the pure synthetic tetrapeptide) versus controls. The treated group showed roughly 28% lower all-cause mortality over the observation period [6]. This is observational, unblinded, and confounded by the Soviet-era research environment. It is the closest thing to a human longevity outcome study available.

Evidence grade: Level 4 (non-randomized historical cohort). Interpret with caution.

What Is Missing

No pharmacokinetic study in humans has been published in a peer-reviewed English-language journal. Bioavailability by route (subcutaneous vs. Sublingual vs. Nasal) is not established from human trials. The community dose of 5 to 10 mg is derived from weight-scaling of animal studies and practitioner experience, not from a dose-finding RCT.

Proposed Mechanisms of Action

Epitalon's biological activity may operate through at least three pathways, each supported by different levels of evidence.

Telomerase Activation

In the 2003 fibroblast study, Epitalon upregulated hTERT (human telomerase reverse transcriptase) gene expression and increased enzymatic telomerase activity in a dose-dependent fashion in vitro [3]. Telomere length in treated cells exceeded untreated controls after serial passage. This is the mechanism that attracts biohackers most directly.

Melatonin and Circadian Modulation

Epithalamin restored circadian melatonin peaks in aging Wistar rats, with nocturnal melatonin values rising from a mean of 42 pg/mL to 87 pg/mL after a 10-day course in one rodent experiment [4]. Epitalon as the synthetic fragment is presumed to carry a similar effect, though direct human melatonin assay data before and after Epitalon administration have not been published in peer-reviewed form.

Antioxidant and DNA-Repair Signaling

A 2004 paper by Khavinson et al. In Mechanisms of Ageing and Development documented that Epitalon reduced 8-oxo-2'-deoxyguanosine (8-oxodG), a biomarker of oxidative DNA damage, in lymphocytes of elderly donors by approximately 1.8-fold versus untreated controls [7]. The reduction in chromosomal aberration rate noted above [3] is consistent with enhanced DNA-repair efficiency.

The Biohacker Stack Protocol: Dose, Route, and Cycle

The following protocol synthesizes published animal and human observational data with community practitioner experience. No dose has been validated in a human RCT. A supervising physician should review this before any patient initiates a course.

Dose Selection

Most community protocols use 5 mg per day as a starting dose and 10 mg per day as the upper range for individuals over 45 who are stacking Epitalon with other longevity peptides. The 5 mg figure derives from Khavinson's animal effective doses scaled to a 70 kg human using body-surface-area conversion (Km factor of 37 per the Reagan-Shaw method published in FASEB Journal) [8]. Going above 10 mg per day has no additional published mechanistic rationale and increases cost without evidence of incremental benefit.

Route of Administration

Subcutaneous injection is the preferred route. Peptides of this molecular weight (<1 kDa) are poorly absorbed orally because of gastrointestinal peptidase degradation. Sublingual administration (holding reconstituted solution under the tongue for 90 to 120 seconds before swallowing) is the second-line option used by individuals who decline injections. No head-to-head bioavailability comparison between these routes exists for Epitalon in humans. Intranasal use is discussed in forums but has no published supporting data at all.

Injection technique: Reconstitute lyophilized Epitalon with bacteriostatic water (typically 2 mL per 10 mg vial) to yield 5 mg/mL. Inject 1 mL subcutaneously into the abdomen or lateral thigh using a 29- or 31-gauge insulin syringe. Rotate sites daily.

Cycle Length and Frequency

The most commonly reported cycle is 10 consecutive days, repeated twice per year (common timing: spring and autumn). Some practitioners extend to 20 consecutive days once per year. The 10-day cycle mimics the duration used in Khavinson's human epithalamin cohort studies [6]. Daily dosing within the cycle is preferred over every-other-day because the telomere elongation data are from continuous-exposure cell models [3].

Do not run Epitalon continuously. Chronic telomerase activation in somatic cells carries theoretical oncogenic risk, a concern the Endocrine Society's 2022 statement on anti-aging interventions acknowledged in the context of telomerase-activating compounds generally [9].

Timing Within the Day

Most practitioners inject Epitalon in the evening, within one to two hours of the intended sleep time, to align with the peptide's proposed circadian and melatonin-supporting effects [4]. Morning injection is an acceptable alternative with no comparative outcome data.

Common Longevity Stacks

Biohackers often pair Epitalon with:

• BPC-157 (500 mcg/day subcutaneous): tissue repair, gut integrity
• Thymosin Alpha-1 (1.5 mg, twice weekly): immune modulation
• Pinealon (10 mg/day, same cycle): another Khavinson pineal peptide, co-administration is described in several of his observational papers [6]
• NAD+ precursors (NMN 500 mg/day or NR 300 mg/day orally): complementary sirtuin pathway support

Do not conflate the evidence bases. Epitalon has more human observational data than most research peptides. BPC-157 and Thymosin Alpha-1 each have different but also limited evidence profiles.

Monitoring Labs Before, During, and After a Cycle

Running labs is non-negotiable for any off-label peptide protocol. The following panel is the minimum standard.

Baseline (Before First Cycle)

| Lab | Rationale | |---|---| | Complete blood count (CBC) with differential | Detect pre-existing cytopenias | | Comprehensive metabolic panel (CMP) | Hepatic and renal safety baseline | | IGF-1 | Epitalon may influence GH axis signaling in rodent models [5] | | Serum melatonin (AM, 8:00 AM sample) | Daytime nadir baseline for circadian assessment | | Telomere length (optional, TruDiagnostic or Life Length) | Expensive but provides the most relevant outcome biomarker | | Fasting glucose and insulin | Safety baseline; metabolic context | | Thyroid panel (TSH, free T3, free T4) | Pineal-thyroid interactions are documented in animal work |

Mid-Cycle (Day 10 if Running a 20-Day Cycle)

A brief check of CBC and CMP at mid-cycle is reasonable for a first-time user. Most practitioners do not repeat labs mid-cycle after the first course if baseline values were normal.

Post-Cycle (4 to 6 Weeks After Completion)

Repeat CBC, CMP, IGF-1, and morning melatonin. If telomere length was measured at baseline, repeat at six months minimum, not at four to six weeks, because telomere assay variation between draws at short intervals exceeds the expected signal from a single cycle.

Expected Timeline of Outcomes

Realistic expectations prevent early abandonment or reckless escalation.

Weeks 1 to 3 (During and Immediately Post-Cycle)

Sleep quality improvement is the most commonly reported early effect in community logs, consistent with the proposed melatonin-modulating mechanism [4]. Subjective recovery from exercise may improve. No objective biomarker change is expected this early.

Months 1 to 3

Some users report improved energy and mood. These are subjective and uncontrolled. Laboratory values (CBC, CMP) should remain stable. No peer-reviewed study documents measurable telomere elongation in humans within three months of a single Epitalon cycle.

Months 6 to 12

The Khavinson rodent data suggest telomere length changes accumulate over multiple cycles and months [3]. If a second cycle was completed at six months, a telomere length assay at 12 months from baseline is the earliest reasonable timepoint for detecting a signal. The 15-year human cohort study suggests mortality benefits require years of periodic use, not a single cycle [6].

Safety, Contraindications, and Regulatory Context

Epitalon has no published serious adverse event reports in the available literature. The Khavinson human cohort studies noted no significant adverse effects in elderly participants receiving epithalamin over 15 years [6]. However, absence of reported adverse events in small, uncontrolled historical cohorts is not the same as a confirmed safety profile.

Theoretical Concerns

Telomerase activation in already-transformed or pre-malignant cells could theoretically accelerate tumor growth. This concern is not hypothetical: hTERT overexpression is present in approximately 90% of human cancers, as documented in a frequently cited 1999 study by Shay and Bacchetti [10]. Anyone with a personal or family history of cancer, or elevated PSA, should not use Epitalon without oncology consultation.

Regulatory Status

Epitalon is not approved by the FDA for any indication [11]. It is sold as a research compound. Compounding pharmacies in the United States may not legally compound it for human use under current FDA compounding regulations [11]. Patients sourcing Epitalon should be aware of purity and sterility risks from non-pharmaceutical-grade suppliers.

Who Should Not Use Epitalon

• Active malignancy or remission <5 years
• Pregnancy or breastfeeding (no safety data)
• Age <30 without a specific clinical rationale (telomere attrition is minimal at younger ages)
• Concurrent use of immunosuppressants (Thymosin Alpha-1 co-administration specifically may alter immune balance)

Comparing Epitalon to Other Telomere-Targeting Interventions

Epitalon is not the only compound biohackers use with telomere rationale. The comparison is worth making explicitly.

TA-65 (cycloastragenol): A plant-derived telomerase activator with one small published RCT in HIV patients (N=39) showing modest telomere lengthening at 36 weeks [12]. Oral bioavailability is established. No lifespan data in humans.

NAD+ precursors: Sirtuin activation through NAD+ may influence telomere integrity indirectly. A 2023 Nature Aging study showed NMN supplementation at 600 mg/day improved muscle NAD+ levels and physical performance in older adults (N=80, 12 weeks) [13], though telomere effects were not the primary endpoint.

Exercise: Aerobic exercise at 150 minutes per week is associated with longer leukocyte telomere length in cross-sectional data, with a 2017 PLOS One analysis of the NHANES cohort (N=5,823) reporting approximately 9 years of biological age difference between highly active and sedentary adults based on telomere length [14]. No cost. Proven safety profile.

Epitalon's advantage over these options is the direct in vitro telomerase activation signal and the depth of Khavinson's longitudinal observational work, albeit in small and historically dated cohorts. Its disadvantage is the complete absence of a human RCT.